Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5386574 | 0.82 | GSR (0.39) | GSRCA2 | |
| SCHEMBL373559 | 0.75 | CYP2D6 (0.32) | — | |
| SCHEMBL9170343 | 0.75 | CYP2D6 (0.32) | — | |
| SCHEMBL542044 | 0.75 | CYP2D6 (0.32) | — | |
| SCHEMBL8897238 | 0.75 | CYP2D6 (0.32) | — | |
| SCHEMBL9422339 | 0.72 | CHRM2 (0.31) | — | |
| Bicarbonate SCHEMBL5386575 | 0.71 | CA2 (0.42) | GSRCA2 | |
| SCHEMBL1037894 | 0.69 | LMNA (0.31) | — | |
| SCHEMBL7763704 | 0.69 | LMNA (0.31) | — | |
| SCHEMBL7360219 | 0.69 | LMNA (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0957903-A4 | PHARMACEUTICAL COMPOSITIONS AND METHODS | CODON PHARMACEUTICALS INC (US) | 2002-10-09 | — | — | EP | claimed |
| US-20020141952-A1 | Regulating the melanin content of mammalian melanocytes by administering alcohols, diols, triols and their analogues | APPLIED GENETICS INCORPORATED DERMATICS | 2002-10-03 | — | — | US | claimed |
| WO-2002051395-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES | CODON PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | WO | claimed |
| EP-0957903-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | Codon Pharmaceuticals, Inc. (US) | 1999-11-24 | — | — | EP | claimed |
| US-5990177-A | CYCLIC AND ACYCLIC MONO-, DI- AND TRIALCOHOLS AS STIMULANTS TO TREAT DISEASES MEDIATED BY DEFICIENCIES IN THE NITRIC OXIDE/CYCLIC GUANOSINE MONOPHOSPHATE/PROTEIN KINASE G SIGNAL TRANSDUCTION PATHWAY; CARDIOVASCULAR; SKIN; NERVOUS SYSTEM | CODON PHARMACEUTICALS, INC. (US) | 1999-11-23 | — | — | US | claimed |
| WO-1998055085-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | CODON PHARMACEUTICALS, INC. (US) | 1998-12-10 | — | — | WO | claimed |
| WO-1998011882-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | CODON PHARMACEUTICALS, INC. (US) | 1998-03-26 | — | — | WO | claimed |
| US-7250157-B2 | Dermatological compositions and methods | APPLIED GENETICS INCORPORATED DERMATICS (US) | 2007-07-31 | — | — | US | disclosed |
| US-20060120976-A1 | Dermatological compositions and methods | APPLIED GENETICS INCORPORATED DERMATICS (US) | 2006-06-08 | — | — | US | disclosed |
| US-6955804-B2 | Dermatological compositions and methods | APPLIED GENETICS INCORPORATED DEMATICS (US) | 2005-10-18 | — | — | US | disclosed |
| US-20040067209-A1 | Dermatological compositions and methods | APPLIED GENETICS INCORPORATED DERMATICS | 2004-04-08 | — | — | US | disclosed |
| US-6623724-B2 | Regulating the melanin content of mammalian melanocytes by administering alcohols, diols, triols and their analogues | APPLIED GENETICS INCORPORATED DERMATICS | 2003-09-23 | — | — | US | disclosed |
| US-20020141952-A1 | Regulating the melanin content of mammalian melanocytes by administering alcohols, diols, triols and their analogues | APPLIED GENETICS INCORPORATED DERMATICS | 2002-10-03 | — | — | US | disclosed |
| US-6294585-B1 | ADMINISTERING NORBORNANE DIOL/TRIOL OR NORBORNENE DIOL/TRIOL DERIVATIVES FOR INCREASING DIFFERENTIATION OF MAMMALIAN NEURONAL CELLS | APPLIED GENETICS INCORPORATED DERMATICS | 2001-09-25 | — | — | US | disclosed |
| US-5990177-A | CYCLIC AND ACYCLIC MONO-, DI- AND TRIALCOHOLS AS STIMULANTS TO TREAT DISEASES MEDIATED BY DEFICIENCIES IN THE NITRIC OXIDE/CYCLIC GUANOSINE MONOPHOSPHATE/PROTEIN KINASE G SIGNAL TRANSDUCTION PATHWAY; CARDIOVASCULAR; SKIN; NERVOUS SYSTEM | CODON PHARMACEUTICALS, INC. (US) | 1999-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020141952-A1 | Regulating the melanin content of mammalian melanocytes by administering alcohols, diols, triols and their analogues | TYR, MITF, MC1R | GSR 1172/4885CA2 4062/4885 |
| US-20060120976-A1 | Dermatological compositions and methods | TYR, MITF, ALPG | GSR 555/4885CA2 3231/4885 |
| US-20040067209-A1 | Dermatological compositions and methods | TYR, MITF, ALPG | GSR 555/4885CA2 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.